跳至主要内容
临床试验/JPRN-jRCTs041180179
JPRN-jRCTs041180179招募中未知

The effect of PHOSPHate control On Renal function in chronic kidney disease patients not on dialysis-PHOSPHOR study - The effect of PHOSPHate control On Renal function in chronic kidney disease patients not on dialysis-PHOSPHOR study

Shigeru Shibata0 个研究点目标入组 160 人开始时间: 2019年3月29日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
160

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20-year-old 至 o setting(—)
性别
All

入选标准

  • 1)Patients in adults (over 20 years old)
  • 2)No gender
  • 3)Patients with eGFR (mL / min / 1.73 m 2) calculated from the serum creatinine value of 15 or more and less than 45 and serum phosphorus value of 4.0 mg / dL or more (including patients taking phosphorus adsorbent)
  • 4)Patients whose eGFR (mL / min / 1.73 m 2) calculated from the serum creatinine value is 15 or more and less than 45 and serum phosphorus value is 4.0 mg / dL or more (patients who are taking phosphorus adsorption drugs have no acute renal function change, CKDPatients whose systemic condition is stable as treatment intervention other than administration of phosphorus adsorption is performed according to clinical guide (edited by Japan Society of Nephrology)
  • 5)Patients receiving one or more appropriate nutritional guidance
  • 6)Patients who agreed to participate in the study

排除标准

  • 1)Patients contraindicated for administration of ferric citrate hydrate
  • 2)Patients with a history of hypersensitivity to the ingredients of this drug
  • 3)Patients with iron overload such as hemochromatosis
  • 4)Defective diabetes (HbA1c> 9.0%)
  • 5)Uncontrolled hypertension (systolic blood pressure of 170 mmHg or more or diastolic blood pressure of 110 mmHg or more)
  • 6)Acute renal failure, nephrotic syndrome, people who have undergone hemodialysis after kidney transplantation
  • 7)tumor (no recurrence, do not exclude those who are untreated for 5 years)
  • 8)Those who are pregnant, lactating, planning pregnancy during the study
  • 9)Persons who are undergoing or are undergoing hormone therapy (HRT) with estrogen
  • 10)Patient using Cinacalcet (Regala R)
  • 11)Patients who are judged inappropriate by the attending physician (dementia, mental retardation, etc.)

研究者

发起方
Shigeru Shibata

相似试验